Financials data is unavailable for this security.
Cash flow in SEKView more
In 2023, cash reserves at Xbrane Biopharma AB fell by 128.59m. Cash Flow from Financing totalled 298.70m or 125.12% of revenues. In addition the company used 406.03m for operations while cash used for investing totalled 16.77m.
Cash flow per share | -0.5419 |
---|---|
Price/Cash flow per share | -- |
Book value per share | 0.1991 |
---|---|
Tangible book value per share | 0.1306 |
More ▼
Balance sheet in SEKView more
Current ratio | 1.60 |
---|---|
Quick ratio | 1.07 |
Total debt/total equity | 0.5551 |
---|---|
Total debt/total capital | 0.357 |
More ▼